# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lou Gehrig (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET018-SYN-TD
- Date: 1939-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gavin Hollister, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Neuromuscular consultation with EMG and nerve conduction studies, and results of the MRI and blood tests. **S**

## History of present illness

Mr. Gehrig returns two weeks after his first visit and is seen the same day by Dr. Nakamura of neuromuscular neurology, who performed EMG and nerve conduction studies this morning. The MRI of the brain and cervical spine a week ago was normal. Since the first visit he has had no new symptoms but feels his grip is a little weaker; he has kept to walking and stretching and has not played or lifted. He has no trouble speaking, swallowing or breathing. He asked to hear the results himself first, and plainly. **S**

| Element | Detail |
|---|---|
| Tests | EMG and nerve conduction studies this morning; MRI of the brain and cervical spine a week ago |
| Symptoms | Grip slightly weaker; cramps; no speech, swallowing or breathing symptoms |
| Activity | Not playing or lifting; walking and stretching |
| His request | Results to him first, plainly |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Hand and left ankle weakness; cramps and twitching; no numbness |
| Ears, nose, mouth, and throat | Negative | No slurred speech, choking or drooling |
| Respiratory | Negative | No breathlessness, including lying flat; no morning headaches |
| Psychiatric | Positive | Worried and sleeping less while waiting for results; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 89.2 kg; BMI 26.6 kg/m². All vital signs are synthetic.

Forced vital capacity (seated): 4.52 L; Forced vital capacity, percent predicted (seated): 88%; ALSFRS-R total (0 to 48): 42; PHQ-9: 7. All results are synthetic.

## Change since baseline

- Forced vital capacity (seated): 4.62 L at baseline, 4.52 L at this visit **S**
- Forced vital capacity, percent predicted (seated): 90% at baseline, 88% at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 70; weight 89.2 kg |
| Neurological | Examined with Dr. Nakamura: wasting of the first dorsal interosseous and thenar muscles, left more than right; fasciculations in both arms, thighs and calves; grip and finger abduction 4/5 on the right and 4-/5 on the left; left ankle dorsiflexion 4-/5; reflexes brisk with spread, Hoffmann sign present on both sides, left plantar extensor; jaw jerk normal; tongue normal; sensation normal |
| Respiratory | No accessory muscle use; normal chest expansion |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Amyotrophic lateral sclerosis, limb onset** (G12.21). EMG shows active denervation (fibrillation potentials and positive sharp waves) with chronic reinnervation and fasciculation potentials in the cervical, thoracic paraspinal and lumbosacral regions; motor responses are reduced in the hands with no conduction block, and sensory responses are normal. The MRI excludes cord compression and a structural lesion; calcium, vitamin B12, TSH and A1c are normal, the protein electrophoresis shows no monoclonal protein, the HIV test is negative, and the creatine kinase of 412 U/L fits denervation. With progressive weakness and upper and lower motor neuron signs in more than one region, this meets the Gold Coast criteria and is clinically probable ALS on the revised El Escorial criteria. ALSFRS-R 42 of 48; seated FVC 4.52 L (88% of predicted); maximal inspiratory pressure -86 cmH2O; a brief cognitive screen is normal. Dr. Nakamura gave him the diagnosis in person with Dr. Hollister present. **S**
   - Riluzole 50 mg twice daily; ALT monthly for 3 months, then every 3 months.
   - Genetic testing with genetic counseling today.
   - Edaravone discussed; he chose to start with riluzole alone and revisit it.
   - Multidisciplinary ALS clinic every 2 to 3 months, first full clinic visit in about five weeks.
   - Breathing tests, weight and ALSFRS-R at every visit.
2. **Progressive weakness and loss of coordination** (M62.81). Superseded by the diagnosis of amyotrophic lateral sclerosis. **S**
   - Problem resolved.
3. **Coping with the diagnosis**. PHQ-9 7 (mild), with worry and short sleep while waiting for results; no thoughts of self-harm. **S**
   - ALS clinic social worker and psychologist offered.
   - PHQ-9 at every visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Upper and lower motor neuron examination by region | At diagnosis, then every visit | Completed today | Upper and lower motor neuron signs in the cervical and lumbosacral regions; bulbar region normal |
| Imaging | EMG and nerve conduction studies | At diagnosis | Completed today | Active and chronic denervation in three regions; normal sensory conduction; no conduction block |
| Imaging | MRI of the brain and cervical spine | At diagnosis, to exclude mimics | Completed today | Normal; no cord compression |
| Laboratory | Blood tests to exclude mimics | At diagnosis | Completed today | Calcium, B12, TSH, A1c normal at intake; no monoclonal protein; HIV negative; creatine kinase 412 U/L |
| Survey | ALSFRS-R | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 42 of 48 at diagnosis |
| Imaging | Seated forced vital capacity | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | 4.52 L, 88% of predicted |
| Examination | Maximal inspiratory pressure; supine capacity and overnight oximetry when values fall or symptoms appear | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Maximal inspiratory pressure -86 cmH2O; no orthopnea |
| Examination | Weight and BMI (gastrostomy discussion if weight falls 5 to 10% or swallowing is unsafe; place while FVC is above 50%) | Every visit | Completed today | 89.2 kg, BMI 26.6 |
| Examination | Speech and swallowing assessment | Every 2 to 3 months in the multidisciplinary ALS clinic | Completed today | Speech and swallowing normal |
| Survey | Cognitive and behavioral screening | At diagnosis and periodically | Completed today | Brief cognitive screen normal; no behavioral change reported by him |
| Survey | Depression (PHQ-9) | Every visit | Completed today | PHQ-9 7, mild; no thoughts of self-harm |
| Laboratory | ALT on riluzole | Monthly for 3 months, then every 3 months | Due | Baseline ALT 32 U/L at intake; riluzole starts today |
| Laboratory | Genetic testing (SOD1 result decides tofersen) | Offer at diagnosis to every person with ALS | Ordered | Panel sent today after genetic counseling |
| Referral | Neuromuscular neurology and multidisciplinary ALS clinic | At diagnosis, then every 2 to 3 months | Completed today | Seen by Dr. Nakamura today; clinic enrolment |
| Self-management | Advance care planning | Early, then at each change | Due | Introduced today; to be held when he is ready |

## Goal progress

- A clear diagnosis, with mimics excluded, within four weeks. Outcome by 1939-05-18: Diagnosis made at two weeks on EMG, MRI and blood tests. **S**
- No falls, using an ankle-foot orthosis, a cane, and a safer home. In progress; target 1939-10-19. **S**
- Weight held within 5% of the weight at diagnosis. In progress; target 1939-10-19. **S**
- Breathing tracked every visit, with noninvasive ventilation started as soon as criteria are met. In progress; target 1939-10-19. **S**
- Goals of care, a health care agent, and his wishes about ventilation and feeding recorded early and revisited. In progress; target 1939-09-21. **S**
- Working in a role that suits him, with accommodations. In progress; target 1939-10-19. **S**

## Medication changes

- Started: Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after meals **S**

## Guideline basis

- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- A proposal for new diagnostic criteria for ALS (Gold Coast criteria) (2020), Clinical Neurophysiology
- El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis (2000), World Federation of Neurology (Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders)
- Evidence-based consensus guidelines for ALS genetic testing and counseling (2023), Annals of Clinical and Translational Neurology

## Follow-up

- Genetic counseling follow-up when the result returns. First full ALS clinic visit in about five weeks, with primary care the following week. **S**
- Next scheduled visit 1939-06-29: six weeks after diagnosis: riluzole safety, genetic test result, multidisciplinary ALS clinic, mobility, mood, and his decision about work. **S**
